Principles and pitfalls in the differential diagnosis and management of childhood obesities

Gabriel Á Martos-Moreno1, Vicente Barrios1, María T Muñoz-Calvo1

  • 1Department of Pediatrics and Pediatric Endocrinology, Hospital Infantil Universitario Niño Jesús; Instituto de Investigación La Princesa; Department of Pediatrics, Universidad Autónoma de Madrid; CIBER Fisiopatología Obesidad y Nutrición; Instituto de Salud Carlos III, Madrid, Spain.

Insights

Childhood obesity is a growing epidemic. Recognizing diverse "obesities" and utilizing genetic, genomic, and metabolomic diagnostics are crucial for personalized pediatric care.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Genetics

Background:

  • Childhood obesity is the most prevalent chronic disease in Western countries, leading to increased comorbidities.
  • Lifestyle factors contribute to energy imbalance, but genetic background significantly influences obesity risk.
  • Understanding diverse pathophysiologic bases of obesity is essential.

Purpose of the Study:

  • To highlight the increasing prevalence of childhood obesity and associated comorbidities.
  • To emphasize the need to differentiate between various causes of obesity.
  • To guide pediatricians in diagnostic and management approaches for childhood obesity.

Main Methods:

  • Review of current understanding of obesity etiology, including lifestyle and genetic factors.
  • Discussion of monogenic, syndromic, and endocrine-related obesity.
  • Emphasis on clinical history, physical examination, and advanced diagnostic studies.

Main Results:

  • Obesity is not a single entity but encompasses diverse conditions with different pathophysiologies.
  • Genetic, genomic, and metabolomic studies are vital for accurate diagnosis.
  • Cognitive behavioral therapy is a fundamental treatment component.

Conclusions:

  • Pediatricians must recognize "obesities" as distinct diseases requiring tailored diagnostic and management strategies.
  • Personalized medicine approaches, including genetic insights, are key for future obesity treatment.
  • Further research into potential pharmacologic targets is needed for translational medicine.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
365
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
440
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.5K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.9K